Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Laurus Labs, Rising...

    Laurus Labs, Rising Pharma launches neuropathic pain capsules in US

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-23T09:30:05+05:30  |  Updated On 17 Aug 2021 10:08 AM IST

    Rising Pharmaceuticals has launched a generic version of Lyrica capsules, in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg, Laurus Labs said in a filing to BSE.


    New Delhi: Drug firm Laurus Labs on Monday said its exclusive distribution partner, Rising Pharmaceuticals, has launched generic Pregabalin capsules indicated for the management of neuropathic pain in the American market.


    Rising Pharmaceuticals has launched a generic version of Lyrica capsules, in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg, Laurus Labs said in a filing to BSE.


    Rising Pharmaceuticals had recently received the final approval from the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA), it added.


    According to IMS Health, Pregabalin capsules had US sales of around USD 5,497 million for the 12 months ending March 2019, Laurus Labs said.


    Also Read: Laurus Labs gets 2 USFDA observations for its API facilities in Visakhapatnam


    "We are happy to develop and manufacture the Pregabalin capsules for our exclusive distribution partner Rising Pharmaceuticals in the US. Currently, we have 5 billion units per year capacity which can be expanded to 8 million units per year based on the demand," Laurus Labs Founder and CEO Satyanarayana Chava said.


    Pregabalin capsules are indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy and management of neuropathic pain associated with spinal cord injury, among other conditions.


    Also Read: USFDA completes inspection at Laurus Labs' AP unit

    Rising Pharmaceuticals sells generic prescription products and over-the-counter pharmaceutical products under the Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers, Laurus Labs said.


    "The commercialization of Pregabalin capsules is one of the largest volumes launches for the company this year and will provide a cost-effective treatment option for people living with debilitating neuropathic pain conditions," Rising Pharmaceuticals CEO Vimal Kavuru said.


    Also Read: Laurus Labs gets no USFDA observations for Vizag unit
    ANDABSElaurus lablyrica capsuleneuropathic painpharmapharma companypharma newspregabalin capsuleRising pharmaSatyanarayana ChavaUSFDAVimal Kavuru
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok